NCT02968173View on ClinicalTrials.gov

A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 9, 2016

Primary Completion Date

July 13, 2017

Study Completion Date

July 13, 2017

Conditions

Respiratory Syncytial Virus (RSV)

Interventions

DRUG

Palivizumab

Palivizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed to an epitope in the A antigenic site of the F (fusion) protein of RSV.